Blood and Marrow Clinical Trials Network - Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN-1302-BioLINCC)
Getting access
Committee review General Research Use (GRU)
- Apply at
- https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs004705.v1.p1
- Agreement
- Data use agreement
- Cost
- No charge
- Renewal
- Every 1 year
From the operator’s published policy metadata.
About this database
| Last updated | 2026-09-11 |
|---|